GLP1R and Cognitive impairment: This meta-analysis examines the association of cardioprotective glucose-lowering agents, including glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors, with reductions in dementia and cognitive impairment.